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STENT PLACEMENT COMPARED WITH BALLOON ANGIOPLASTY
FOR OBSTRUCTED CORONARY BYPASS GRAFTS
MICHAEL P. SAVAGE, M.D., JOHN S. DOUGLAS, JR., M.D., DAVID L. FISCHMAN, M.D., CARL J. PEPINE, M.D.,
SPENCER B. KING III, M.D., JEFFREY A. WERNER, M.D., STEVEN R. BAILEY, M.D., PAUL A. OVERLIE, M.D.,
SARAH H. FENTON, M.D., JEFFREY A. BRINKER, M.D., MARTIN B. LEON, M.D., AND SHELDON GOLDBERG, M.D.,
FOR THE SAPHENOUS VEIN DE NOVO TRIAL INVESTIGATORS*

ABSTRACT
Background Treatment of stenosis in saphenousvein grafts after coronary-artery bypass surgery is a
difficult challenge. The purpose of this study was to
compare the effects of stent placement with those of
balloon angioplasty on clinical and angiographic outcomes in patients with obstructive disease of saphenous-vein grafts.
Methods A total of 220 patients with new lesions
in aortocoronary–venous bypass grafts were randomly assigned to placement of Palmaz–Schatz stents or
standard balloon angioplasty. Coronary angiography
was performed during the index procedure and six
months later.
Results As compared with the patients assigned
to angioplasty, those assigned to stenting had a higher rate of procedural efficacy, defined as a reduction
in stenosis to less than 50 percent of the vessel
diameter without a major cardiac complication (92
percent vs. 69 percent, P0.001), but they had more
frequent hemorrhagic complications (17 percent vs.
5 percent, P0.01). Patients in the stent group had a
larger mean (SD) increase in luminal diameter
immediately after the procedure (1.920.30 mm, as
compared with 1.210.37 mm in the angioplasty
group; P0.001) and a greater mean net gain in luminal diameter at six months (0.850.96 vs. 0.540.91
mm, P  0.002). Restenosis occurred in 37 percent of
the patients in the stent group and in 46 percent of
the patients in the angioplasty group (P  0.24). The
outcome in terms of freedom from death, myocardial infarction, repeated bypass surgery, or revascularization of the target lesion was significantly
better in the stent group (73 percent vs. 58 percent,
P  0.03).
Conclusions As compared with balloon angioplasty, stenting of selected venous bypass-graft lesions resulted in superior procedural outcomes, a
larger gain in luminal diameter, and a reduction in
major cardiac events. However, there was no significant benefit in the rate of angiographic restenosis, which was the primary end point of the study.
(N Engl J Med 1997;337:740-7.)
©1997, Massachusetts Medical Society.

T

HE treatment of patients with obstructive
disease of coronary-artery bypass grafts poses a challenge of increasing magnitude as
the population of patients who have undergone bypass surgery continues to grow. Within a
decade after surgery, half of all saphenous-vein bypass
grafts have severe atherosclerotic disease.1-7 Management of graft disease is problematic, since repeated
surgery entails substantial risk and the results of conventional angioplasty have been disappointing.8-12 As
compared with angioplasty in native coronary arteries, balloon dilation of vein grafts is associated with
increased rates of procedural complications and restenosis.12-16 Previous randomized trials of stent implantation, as compared with balloon angioplasty,
have shown superior outcomes in native vessels, and
observational reports have suggested favorable results
in diseased vein grafts.17-22 Accordingly, we conducted a prospective, randomized trial to compare stent
implantation with balloon angioplasty for the treatment of obstructive disease of venous bypass grafts.
METHODS
Twelve clinical centers with experience with the implantation
of Palmaz–Schatz stents participated in the trial (see the Appendix). The study protocol was approved by the institutional review
board at each site.
Selection of Patients
The study population consisted of patients with new lesions in
aortocoronary venous bypass grafts who had angina pectoris, ob-
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jective evidence of myocardial ischemia, or both. Angiographic
entry criteria included stenosis of 60 percent or more of the luminal diameter in vessels from 3.0 to 5.0 mm in diameter. Exclusion criteria were myocardial infarction within the previous seven
days; a contraindication to therapy with aspirin, dipyridamole, or
warfarin; an ejection fraction of less than 25 percent; diffuse disease that would require more than two stents; evidence of thrombus; and outflow obstruction of the graft due to distal anastomotic
stenosis or poor runoff in the recipient native vessel. After giving
informed consent, patients were randomly assigned to either angioplasty or stent placement.

The principal clinical end point was a composite outcome defined as the occurrence of death, myocardial infarction, repeated
bypass surgery, or revascularization of the target lesion. Myocardial infarction was defined as the presence of new Q waves lasting
0.04 second or more or an elevation of the serum creatine kinase
level to three times the upper limit of normal with an elevated MB
fraction (measured 6, 12, and 24 hours after the procedure). Secondary clinical outcomes included the duration of hospitalization
and the frequency of bleeding and peripheral vascular complications.
Statistical Analysis

Protocols
The stent used in this trial was the 15-mm-long Palmaz–Schatz
coronary stent (Johnson & Johnson Interventional Systems, Warren, N.J.).23-25 Patients assigned to stent placement received aspirin (325 mg daily) and dipyridamole (75 mg three times per day),
beginning at least 24 hours before the procedure. During the
procedure, patients received intravenous dextran 40 and heparin
to maintain an activated clotting time of more than 300 seconds.
Warfarin therapy was begun on the day of the procedure, and heparin therapy was continued until a therapeutic prothrombin time
(international normalized ratio, 2.0 to 3.5) was achieved. Dipyridamole and warfarin were continued for one month, and aspirin
indefinitely.
Angioplasty was performed with use of conventional balloon
catheters. Patients in whom angioplasty was successful received
aspirin (325 mg daily) indefinitely. Crossover to stent placement
was permitted as a bailout procedure in the event of abrupt or
threatened vessel closure. Patients assigned to the angioplasty group
who required stent placement as a bailout procedure received warfarin and dipyridamole for one month in addition to aspirin.
Follow-up
Patients were evaluated clinically one, three, and six months
after the procedure. Coronary angiography was repeated at six
months. Angiography was performed earlier if there were recurrent symptoms. However, if restenosis was not found during repeated angiography performed within four months of the procedure, angiography was repeated at six months.
Angiographic Analysis
Angiography was performed in orthogonal views at base line, after the intervention, and at six months. Quantitative coronary analysis was performed at the core angiographic laboratory at Jefferson
Medical College with use of a validated edge-detection algorithm.18,24-28 The diameters of the normal-appearing segments proximal and distal to the lesion were averaged to determine the reference vessel diameter. The minimal luminal diameter, reference
diameter, and degree of stenosis as a percentage of the vessel diameter were calculated as mean values from orthogonal projections.

The target sample size of 210 patients was based on the assumption that the rate of restenosis in vein-graft lesions in the angioplasty group would be 50 percent or more and that the rate
of restenosis in stented vessels would be less than 25 percent.20-22
Allowing for a procedural failure rate of 10 percent and an angiographic-restudy rate of 80 percent, the enrollment of 210 patients
would yield more than 150 patients with angiographic follow-up
and give the study a statistical power of 0.90 and an alpha level
of 0.05.
Data were recorded prospectively and forwarded to the datacoordinating center. Case-report forms and charts were independently audited by research monitors. Adverse events were reviewed in blinded fashion by the steering committee.
Outcomes were analyzed according to the intention-to-treat
principle. Categorical data were assessed by the chi-square or Fisher’s exact test. Rates of clinical events in the treatment groups at
6 months (follow-up window, 120 to 240 days) were compared
with use of the log-rank test. Two-tailed P values were calculated,
with values below 0.05 considered to indicate statistical significance.
The quantitative angiographic results for 122 lesions treated
with stenting and 120 treated with angioplasty were analyzed by
multivariate analysis of variance with use of the BMDP program
4V.29 The results for individual lesions were not entirely independent, since 18 percent of patients had multiple lesions. We
therefore used a linear-structure model of vessel measurements
that included a patient factor, which was tested under a second
“between” (or grouping) factor, treatment assignment (stenting
vs. angioplasty). In addition, the model contained a “within” (or
repeated-measures) factor, time (base line, immediately after the
procedure, or follow-up). The three dependent variables in the multivariate model were the diameter of the reference vessel, the minimal luminal diameter, and the percentage of stenosis. Because the
term for the interaction of time and treatment assignment in the
model was significant for all three variables (P0.002), the multiple analysis of variance was performed for each level of the time
factor separately. Protection against the detection of spurious differences due to multiple comparisons was afforded by the “protected F-tests” concept — that is, the principle of not interpreting
effects further when the overall F tests failed to reject the null hypothesis.30

RESULTS

End Points
The primary angiographic end point was restenosis, defined as
stenosis of 50 percent or more of the luminal diameter at followup. When multiple lesions were treated, restenosis was considered
present in a patient if any lesion had restenosis. Secondary angiographic end points included the rate of procedural success and
the change in the minimal luminal diameter from the base-line
value immediately after the procedure and at six months. Procedural success was defined as a reduction in the degree of stenosis
to less than 50 percent, as assessed by quantitative angiography.
Procedural efficacy was also assessed as an initial outcome; this
combined angiographic and clinical end point was intended to reflect the overall predictability of the planned intervention. Procedural efficacy was defined as angiographic success with the assigned therapy, without crossover to the alternative therapy, and
the absence of in-hospital complications.

Between January 1993 and June 1995, 220 patients were enrolled; 110 patients were assigned to
stent placement and 110 patients to angioplasty. After randomization, five patients (two in the stent
group and three in the angioplasty group) were excluded because of violations of the protocol with respect to enrollment criteria. The base-line clinical and
angiographic characteristics of the groups are shown
in Tables 1 and 2, respectively. The treated grafts were
relatively old: on average, 10.1 years in the stent
group and 9.4 years in the angioplasty group. The
groups were well matched except for a slightly higher
prevalence of diabetes in the angioplasty group.
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Procedural Outcomes
TABLE 1. BASE-LINE CLINICAL CHARACTERISTICS
OF THE PATIENTS.*
STENT
GROUP
(N  108)

CHARACTERISTIC

Age (yr)
Male sex (%)
Hyperlipidemia (%)
Hypertension (%)
Diabetes mellitus (%)
Current smoking (%)
Prior myocardial infarction (%)
Myocardial infarction within
previous 6 wk (%)
Unstable angina (%)
Ejection fraction

ANGIOPLASTY
GROUP
(N  107)

669
82
65
61
23
17
68
18

669
79
64
55
36†
15
70
19

82
0.530.14

77
0.520.14

*Plus–minus values are means SD. Five of the 220 patients originally
enrolled were excluded because of protocol violations.
†P  0.05 for the comparison between the groups.

TABLE 2. BASE-LINE ANATOMICAL CHARACTERISTICS
OF THE PATIENTS.*

CHARACTERISTIC

Age of graft (yr)
Recipient native vessel (%)
Left anterior descending artery
Left circumflex artery
Right coronary artery
Multiple
Distal anastomosis (%)
Single
Multiple
Location of target lesion (%)
Aortic anastomosis
Proximal third
Middle third
Distal third
Coronary anastomosis
No. of lesions treated (%)
1
2
3
Length of lesion (mm)
Degree of stenosis (% of diameter)
Eccentricity (%)
Ulceration (%)
Thrombus (%)
Definite
Possible
Lesion on bend 45 degrees (%)
Tortuous graft (%)

STENT
GROUP
(N  108)

ANGIOPLASTY
GROUP
(N107)

10.14.2

9.44.3

33
31
28
8

36
29
27
8

84
16

82
18

7
43
29
19
2

9
29
36
21
5

82
14
4
9.65.4
7212
73
35

83
10
7
9.85.2
7112
82
39

6
18
11
39

8
22
10
39

*Plus–minus values are means SD. There were no significant differences between the groups. Five of the 220 patients originally enrolled were
excluded because of protocol violations.
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Stents were placed in 105 of 108 patients assigned
to this therapy (97 percent). Two patients assigned
to the stent group were treated with angioplasty because the characteristics of the lesions were deemed
unfavorable for stent placement at the time of the
procedure, and one patient underwent bypass surgery. Balloon angioplasty was performed in 103 of
107 patients assigned to this therapy (96 percent).
Of the four patients assigned to angioplasty who did
not undergo the procedure, two were treated medically and two underwent bypass surgery. Seven patients in the angioplasty group (7 percent) required
bailout stent placement.
Rates of procedural success and early clinical outcomes are shown in Table 3. Angiographic procedural success was achieved in 97 percent of the patients assigned to stent placement and 86 percent of
those assigned to angioplasty (P0.01). The rate of
procedural efficacy was also significantly higher in
the stent group than in the angioplasty group (92
percent vs. 69 percent, P0.001). Thus, 31 percent
of patients assigned to angioplasty had an unsuccessful angiographic result, had a major complication, or
required unplanned revascularization. In contrast,
only 8 percent of the stent group had an unsuccessful angiographic result, a complication, or a need for
alternative therapy.
There were no significant differences between the
groups in terms of major in-hospital cardiac complications. However, there was a trend toward fewer
non–Q-wave myocardial infarctions in the stent
group (2 percent, as compared with 7 percent in the
angioplasty group; P  0.10). Abrupt reclosure of
the vessel occurred in one patient in each group; the
incidence of thrombosis in the stented vessel within
one month was 0.9 percent. Bleeding and vascular
complications were significantly more common in
the stent group (17 percent vs. 5 percent, P0.01).
Angiographic Results

Coronary angiography was repeated a mean (SD)
of 62 months after the initial procedure in 166 of
193 patients eligible for angiographic follow-up (86
percent). The follow-up rate was similar for the
stent and angioplasty groups (88 percent and 84
percent, respectively; P not significant). The quantitative angiographic results are shown in Table 4.
Immediately after the intervention, a larger mean
gain in luminal diameter was achieved in the patients
assigned to stent placement (1.920.30 mm vs.
1.210.37 mm, P0.001). Although the late loss
of luminal diameter was higher after stenting, there
was a significantly greater mean net gain in luminal
diameter at six months with stenting (0.850.96
mm vs. 0.540.91 mm, P  0.002). The minimal
luminal diameter at six months was 1.731.02 mm
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TABLE 3. PROCEDURAL OUTCOMES

VARIABLE

Procedural outcome†
Angiographic success (%)
Procedural efficacy (%)
Crossover to stenting (%)
Hospital stay (days)
In-hospital events (%)
Death
Q-wave myocardial infarction
Non–Q-wave myocardial infarction
CABG
Abrupt vessel closure
Repeated PTCA
Any event
Bleeding and vascular complications at
0–30 days (%)
Stroke
Vascular surgery
Transfusion
Any event

AND

EARLY CLINICAL EVENTS.*

STENT
GROUP
(N108)

ANGIOPLASTY
GROUP (N107)

P VALUE

97
92
—
76

86
69
7
47

0.01
0.001
—
0.001

2
2
2
2
1
1
6

2
1
7
4
1
1
11

0.79
0.99
0.10
0.45
0.99
0.99
0.13

0
5
15
17

0
3
3
5

0.99
0.72
0.01
0.01

*Plus–minus values are means SD. CABG denotes coronary-artery bypass graft surgery, and
PTCA percutaneous transluminal coronary angioplasty. Five of the 220 patients originally enrolled
were excluded because of protocol violations.
†Angiographic success was defined as residual stenosis of less than 50 percent of the vessel diameter
immediately after the procedure. Efficacy was defined as angiographic success achieved with the assigned therapy and the absence of a major in-hospital complication.

TABLE 4. CHARACTERISTICS OF LESIONS AT BASE LINE
IMMEDIATELY AFTER THE PROCEDURE AND

VARIABLE

At base line
Diameter of reference vessel — mm
Minimal luminal diameter — mm
Degree of stenosis — % of diameter
After procedure
Diameter of reference vessel — mm
Minimal luminal diameter — mm
Degree of stenosis — % of diameter
Elastic recoil — %
Dissection — % of lesions
At 6 mo
Diameter of reference vessel — mm
Minimal luminal diameter — mm
Degree of stenosis — % of diameter
Restenosis in lesion — no./total no. (%)
Restenosis in patient — no./total no. (%)
Change in minimal luminal diameter — mm
Immediate gain
Late loss
Net gain

AND ANGIOGRAPHIC
AT SIX MONTHS.*

RESULTS

STENT GROUP

ANGIOPLASTY
GROUP

P VALUE

3.180.56
0.900.42
7212

3.190.61
0.940.44
7112

0.36
0.34
0.47

3.190.55
2.810.49
1213
139
7

3.190.61
2.160.57
3217
3016
29

0.55
0.001
0.001
0.001
0.001

3.140.54
1.731.02
4630
35/98 (36)
32/86 (37)

3.110.57
1.490.88
5126
43/91 (47)
37/80 (46)

0.95
0.01
0.02
0.11
0.24

1.920.30
1.060.92
0.850.96

1.210.37
0.660.87
0.540.91

0.001
0.001
0.002

*Plus–minus values are means SD. The results are means for all lesions, unless otherwise specified. In the stent group, 122 lesions were treated in 108 patients; in the angioplasty group, 120 lesions in 107 patients.
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100
At 6 months

75

At base line

50
After
procedure

25

Stenting
Angioplasty

0
0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

Minimal Luminal Diameter (mm)

Late Clinical Events

Figure 1. Cumulative Distribution of Minimal Luminal Diameters in the Treatment Groups at Base Line, Immediately after
the Procedure, and at Six Months.
The degree of initial luminal narrowing was similar in the two
treatment groups, as demonstrated by the near-superimposition of the curves at base line. The curves separate after the
procedure and at follow-up, indicating the larger luminal diameter achieved by stent placement.

in the stent group and 1.490.88 mm in the angioplasty group (P0.01). Cumulative frequency distributions of minimal luminal diameters in the two
groups are shown in Figure 1.
When the results were analyzed according to
intention-to-treat principles, restenosis was found in
37 percent of the patients in the stent group and
in 46 percent of the patients in the angioplasty
group (P0.24). The relative risk of restenosis in a
patient after stenting was 0.84 (95 percent confidence interval, 0.64 to 1.11); after adjustment for
diabetes mellitus, the relative risk was 0.83 (95 percent confidence interval, 0.63 to 1.08). Restenosis
was observed in 36 percent of the lesions in the
stent group and in 47 percent of the lesions in the
angioplasty group (P0.11). The relative risk of restenosis in a lesion after stenting was 0.82 (95 percent confidence interval, 0.64 to 1.05); after adjustment for diabetes, the relative risk was 0.83 (95
percent confidence interval, 0.64 to 1.06). When
only patients who received the assigned therapy ac-

TABLE 5. MAJOR CARDIAC EVENTS

EVENT

cording to the protocol were analyzed, the differences in the rates of restenosis were statistically significant: 34 percent for the patients treated with
stenting as compared with 48 percent for those
treated with angioplasty (P0.05). The relative risk
of restenosis was 0.77 (95 percent confidence interval, 0.60 to 0.99) for the stent group as compared
with the angioplasty group; after adjustment for diabetes, the relative risk was 0.78 (95 percent confidence interval, 0.60 to 1.01).
The cumulative incidence of major cardiac events
at follow-up is shown in Table 5. The rate of eventfree survival (freedom from death, myocardial infarction, repeated bypass surgery, and revascularization
of the target lesion) was significantly greater for patients assigned to stenting than for patients assigned
to balloon angioplasty (Fig. 2). At 240 days, the rate
of event-free survival by Kaplan–Meier analysis was
73 percent in the stent group as compared with 58
percent in the angioplasty group (P0.03). The relative risk of a major cardiac event associated with
stenting was 0.82 (95 percent confidence interval,
0.68 to 0.98); after adjustment for diabetes, the relative risk was 0.82 (95 percent confidence interval,
0.68 to 0.99).
DISCUSSION

Recurrent myocardial ischemia after coronaryartery bypass surgery is a common clinical problem
because of the large number of patients with bypass
grafts implanted many years earlier. Angiographic
studies have found that within 10 years after the operation, half of all vein grafts are totally occluded or
have severe atherosclerotic disease.1-7 Repeated bypass
surgery is more technically challenging than a first operation, is associated with higher morbidity and mortality, and provides less symptomatic relief.8-11 Angioplasty is therefore often attempted in lieu of
reoperation. However, the results of balloon angioplasty in saphenous-vein bypass grafts are less favor-

UP TO

240 DAYS

AFTER THE

STENT
GROUP
(N108)

PROCEDURE.

ANGIOPLASTY
GROUP
(N107)

P VALUE

9
4
11
12
16
26
39

0.44
0.99
0.13
0.24
0.54
0.09
0.04

percent

Death
Q-wave myocardial infarction
Non–Q-wave myocardial infarction
Coronary bypass surgery
Repeated angioplasty
Target-lesion revascularization
Any event
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7
5
6
7
13
17
26
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able than those in native vessels, with rates of restenosis exceeding 50 percent.12-16 Furthermore, the
rates of complications and restenosis increase once
the age of a graft exceeds three to five years.13,15,16
Given the limitations of these therapies, stent implantation has been suggested as an alternative therapeutic approach. Observational studies of patients
who have received the Palmaz–Schatz stent have reported relatively low rates of restenosis.19-22 However,
there have been no direct comparisons of angioplasty and stent implantation for the treatment of disease in saphenous-vein grafts.
The results of our randomized trial demonstrate
that elective stent placement produces better angiographic and clinical outcomes than balloon angioplasty in the treatment of new lesions in aortocoronary
venous bypass grafts. Stenting was associated with
superior initial angiographic results, higher rates of
procedural success, and a trend toward fewer periprocedural non–Q-wave myocardial infarctions. Although
the rates of restenosis were not significantly different
with the two treatment strategies, at six months the
luminal diameter was significantly larger in the stent
group. Most important, clinical outcome was improved by stenting. The proportion of patients who
were free from death, myocardial infarction, repeated
bypass surgery, and revascularization of the target lesion was significantly greater in the stent group.
The findings of this study are concordant with
those of the Stent Restenosis Study (STRESS) and
the Belgium–Netherlands Stent (Benestent) trial,
which found superior outcomes with stenting in native coronary arteries.17,18 On the other hand, our
findings contrast with data on directional atherectomy in bypass-graft lesions reported by the second
Coronary Angioplasty versus Excisional Atherectomy Trial (CAVEAT II).31,32 Although both stenting
and atherectomy produced better initial angiographic results in vein grafts than angioplasty, atherectomy
was associated with more procedural complications,
particularly distal embolization.31,32 The trend toward more non–Q-wave infarctions in patients treated with atherectomy contrasts with the trend toward
fewer non–Q-wave infarctions in patients treated
with stenting in our trial. Possibly the screen-like
configuration of the stent may entrap friable graft
atheroma, thereby reducing the likelihood of dislodgement and embolization of larger debris.
Several limitations of stenting should be emphasized. The intense anticoagulation protocol used in
this trial resulted in a significant increase in hemorrhagic complications. Similar findings were observed
in the Benestent and STRESS trials, which used similar anticoagulant regimens.17,18 Although this protocol was standard therapy when the trial was performed, subsequent studies have shown the superior
safety and efficacy of aspirin and ticlopidine in conjunction with high-pressure stent deployment.33-35 A

Probability of Event-free Survival
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1.0
0.9

Stenting

0.8
0.73

0.7
0.6

0.58

Angioplasty

0.5
0.4
0.3
0.2
P  0.03

0.1
0.0
0

60

120

180

240

Days after Procedure
Figure 2. Kaplan–Meier Survival Curves for Freedom from Major Cardiac Events.
The rate of event-free survival was significantly higher among
patients assigned to stenting than among those assigned to
angioplasty. The relative risk of a major cardiac event after
stenting was 0.82 (95 percent confidence interval, 0.68 to 0.98);
after adjustment for diabetes, the relative risk was 0.82 (95 percent confidence interval, 0.68 to 0.99).

reduction in the rate of hemorrhagic complications
after vein-graft stenting has also been reported with
antiplatelet therapy alone.36
The results of this study cannot be extrapolated to
populations excluded from the trial, such as patients
with restenotic or diffusely diseased grafts. In a prospective study of Palmaz–Schatz stents in vein-graft
disease, we found a significantly higher rate of restenosis of single stents placed in recurrent lesions than
of those placed in new lesions (51 percent vs. 22
percent).20
It is important to emphasize limitations due to the
open nature of this trial, since patients and operators
were not blinded to the treatment. Thus, the possibility of bias cannot be excluded despite the prospective,
randomized trial design. This caveat is pertinent not
only to the angiographic results but also to clinical
end points, since the decision to perform additional
procedures could have been influenced by the knowledge that the stent was present. On the other hand,
several factors support our findings. First, quantitative
measurements of the severity of stenosis were performed by a core laboratory using a validated computerized program that automatically determined the
luminal dimensions. Second, the results of this trial of
stenting in vein grafts closely corroborate the findings
of the two landmark trials of stents in native vessels.17,18 In all three studies, stent placement was associated with a larger gain in minimal luminal diameter,
a reduction of 25 to 30 percent in the risk of restenosis, and fewer cardiac events. Finally, in this trial
knowledge of the patients’ treatment assignment did
not appear to influence the use of further procedures
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to treat restenosis. In patients with angiographic evidence of restenosis, the proportion of patients undergoing revascularization of the target lesion was
virtually identical in the two study groups: 59 percent after stenting and 58 percent after angioplasty.
A final limitation of this study is that stenting was
less effective in reducing the rate of restenosis than
we anticipated. With respect to a priori assumptions,
the rate of restenosis in the balloon angioplasty group
was lower than expected, whereas the rate of restenosis in the stent group was higher than expected.12-16,22,31 According to quantitative coronary analysis by the same core angiographic laboratory used
in this study, restenosis in the multicenter registry of
vein-graft stenting was only 22 percent,20 a rate substantially lower than that in the current trial. A similar phenomenon was observed in the STRESS trial,
in which there was a significant discordance in rates
of restenosis between the registry and randomized
studies. The rate of restenosis of stented vessels in native coronary arteries was 32 percent in the prospective randomized trial, as compared with only 14 percent in the registry, despite similar inclusion criteria
and analysis by the same core laboratory.18,28 These
results suggest a bias toward favorable outcomes in
observational registries of the use of interventional
devices. As a result, the use of the intention-to-treat
principle in a prospective, randomized trial may yield
results that are less favorable than expected.
As compared with conventional angioplasty, stent
placement in new vein-graft lesions was associated
with better initial angiographic results and higher
rates of procedural success. Although the luminal diameter at six months was larger in the stent group,
there was no significant difference in the rate of restenosis, the primary angiographic end point. However, major cardiac events occurred less frequently in
the stent group. Continued follow-up is planned to
assess longer-term clinical outcomes.
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APPENDIX
The following institutions and investigators, in addition to the authors,
participated in the Saphenous Vein De Novo (SAVED) trial: Arizona Heart
Institute, Phoenix; Emory University Hospital, Atlanta; Johns Hopkins
Hospital, Baltimore; Methodist Hospital, Lubbock, Tex.; the Heart Group,
Bellevue, Wash.; Thomas Jefferson University Hospital, Philadelphia —
A. Zalewski and P. Walinsky; University of California, San Diego, La Jolla;
University of Florida, Gainesville — R. Kerensky and T. Wargovich; University of Texas, Houston; University of Texas, San Antonio — S.R. Kiesz;
William Beaumont Hospital, Royal Oak, Mich.; Yale University, New Haven, Conn. — H. Cabin; Beth Israel Deaconess Medical Center, Boston —
D. Baim; Core Angiographic Laboratory, Thomas Jefferson University
Hospital, Philadelphia — D. Rehmann; and Data Coordinating Center,
Johnson & Johnson Interventional Systems, Warren, N.J. — J. Gwo,
J. Lind, and C. Ray.
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